NUV 868
Alternative Names: NUV-868Latest Information Update: 06 Jun 2023
At a glance
- Originator Nuvation Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 01 Jun 2023 Nuvation Bio plans to file an IND application for Solid tumours by the end of year
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 04 Aug 2022 Nuvation Bio plans a phase II and IIb trial in Solid tumours (Combination therapy, Monotherapy)